期刊文献+

聚乙二醇化重组人粒细胞刺激因子工作对照品的制备和标定

Preparation and Calibration for Working Reference of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor
下载PDF
导出
摘要 目的 制备聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)工作对照品,替换现有的rhG-CSF国家标准品,用于蛋白质含量、理化指标等测定.方法 按2015年版《中国药典》四部有关要求,进行工作对照品的制备、分装、冻干、质量检测、结构表征、活性测定.并采用凯氏定氮法进行蛋白质含量标定.结果 制备的工作对照品各项检测指标均符合标准,结构确证与理论相符,凯氏定氮协作标定结果:蛋白质含量为1.9339 mg/支,标准差为0.02295 mg/支,RSD=1.19%,符合统计学要求.结论 该批PEG-rhG-CSF工作对照品各项指标均符合要求,可用于鉴别、蛋白含量测定、各项纯度检查等日常检验和质量研究. Objective To prepare the working reference of pegylated recombinant human granulocyte colonystimulating factor(PEG-rhG-CSF)to replace the existing rhG-CSF national standard for the determination of protein content and physical and chemical propertities.Methods According to the requirements listed in Chinese Pharmacopoeia(VolumeⅣ,2015 Edition),the preparation,sub packaging,freeze-drying,quality testing,structural characterization and activity determination of the working reference were carried out.The protein content was determined by Kjeldahl method.Results All the physical and chemical indicators of the prepared working reference met the standards,and the structure was confirmed to be consistent with the theory.The protein content was 1.9339 mg per vial and the standard deviation was 0.02295 mg per vial,with RSD of 1.19%,which met the statistical requirements.Conclusion This batch of PEG-rhG-CSF working reference standard meets the requirements and can be used for daily inspection and quality research such as identification,determination of protein content and purity.
作者 张培彪 柳常青 刘忠 张贵民 ZHANG Pei-biao;LIU Chang-qing;LIU Zhong;ZHANG Gui-min(Shandong Engineering Laboratory of Protein Drugs,Shandong New Time Pharmaceutical Co.,Ltd.,Linyi 273400,China)
出处 《食品与药品》 CAS 2020年第3期208-211,共4页 Food and Drug
关键词 聚乙二醇化 工作对照品 蛋白质含量 凯氏定氮 pegylation working reference protein content Kjeldahl method
  • 相关文献

参考文献2

二级参考文献17

  • 1饶海林,张珂,曾海鹏,邓杰,张雪梅.大肠杆菌表达的人IL-6复性条件研究[J].微生物学免疫学进展,2007,35(3):27-30. 被引量:2
  • 2张珂,饶海林,曾海鹏,袁涛,张雪梅.PEG化重组人白细胞介素-6制品游离PEG测定方法的研究[J].微生物学免疫学进展,2007,35(3):35-38. 被引量:2
  • 3袁涛,王智杰,邓杰,张珂,李征,张雪梅.PEG-rhIL-6与rhIL-6在化疗模型小鼠中体内药效的比较研究[J].微生物学免疫学进展,2011,39(2):41-45. 被引量:2
  • 4Ishibashi T, Shikama Y, Kimura H, et al. Thrombopoietic effects of interleukin-6 in long-term administration in mice [J]. Exp Hematol, 1993, 21 (5): 640-646.
  • 5Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets [J]. Blood, 1990, 75 (8): 1602-1605.
  • 6Bracho F, Krailo MD, Shen V, et al. A phase I clinical, phar- macological, and biological trial of interleukin-6 plus granulocyte- colony stimulating factor after Ifosfamide, Carboplatin, and Etopo- side in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/ IV con- stitutional toxicities [J]. Clin Cancer Res, 2001, 7 ( 1 ) : 58-67.
  • 7袁涛 王智杰 赵兆等.pET-11b-rhIL-6/BL21(DE3)512程菌高密度发酵工艺研究.四川大学学报:自然科学版,2008,45:279-282.
  • 8张雪梅,袁涛,张珂,等.白细胞介素-6聚乙二醇结合物及其制备方法和应用[P].中国,ZL200680013336.5.
  • 9ChP(中国药典).2005.VolⅢ(三部):163.
  • 10ZHOU Hai-jun(周海均).Technical Requirements for Registration of Pharmaceuticals for Human Use-Quality(药品注册的国际技术要求-质量部分).Beijing(北京):People’s Medical Publishing House(人民卫生出版社),2000.143.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部